Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
03/2002
03/21/2002WO2002022611A2 Caspase inhibitors and uses thereof
03/21/2002WO2002022610A1 Isoxazoles and their use as inhibitors of erk
03/21/2002WO2002022608A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022607A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022606A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022605A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022604A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022603A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022602A2 Triazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022601A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022600A2 Chemokine receptor binding heterocyclic compounds
03/21/2002WO2002022599A2 Chemokine receptor binding heterocyclic compounds
03/21/2002WO2002022580A1 Antibacterials mutilins
03/21/2002WO2002022574A1 Tricyclic heterocyclic compound, process for producing the same, and use thereof
03/21/2002WO2002022573A2 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
03/21/2002WO2002022567A1 Novel thio derivatives of sordarin as antifungal agents
03/21/2002WO2002022558A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
03/21/2002WO2002022171A2 Pharmaceutical composition having specific water activity
03/21/2002WO2002022169A2 VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS
03/21/2002WO2002022168A2 Vaccine against streptococcus pneumoniae
03/21/2002WO2002022167A2 Vaccine against streptococcus penumoniae
03/21/2002WO2002022164A1 Composition comprising immunogenic microparticles
03/21/2002WO2002022161A2 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases
03/21/2002WO2002022160A2 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism
03/21/2002WO2002022150A2 Medicament containing activated antithrombin iii
03/21/2002WO2002022147A1 Antibacterial combination comprising neem plant extract
03/21/2002WO2002022140A1 Homeostasis-maintaining agents
03/21/2002WO2002022134A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals
03/21/2002WO2002022130A2 Means for regulating immune defences
03/21/2002WO2002022126A1 Gatifloxacin pentahydrate
03/21/2002WO2002022125A1 Methods for delaying recurrence of herpes virus symptoms
03/21/2002WO2002022118A1 Fungicidal agent containing n-chlorotaurine and use thereof
03/21/2002WO2002022115A2 Methods and compositions for treating nail fungus
03/21/2002WO2002022112A2 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
03/21/2002WO2002022107A2 Pharmaceutical composition having modified carrier
03/21/2002WO2002022080A2 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
03/21/2002WO2002022077A2 Compositions and methods for inhibition of hiv-1 infection
03/21/2002WO2002021926A2 An antimicrobial composition
03/21/2002WO2002002142B1 Papillomavirus vaccine
03/21/2002WO2001093843A3 Benzoic acid esters having antiplasmid effect
03/21/2002WO2001087846A3 Tricyclic pyrazole derivatives as protein kinase inhibitors
03/21/2002WO2001082962A3 Immunizing against hiv infection
03/21/2002WO2001081346A3 Inhibitors of human phosphatidyl-inositol 3-kinase delta
03/21/2002WO2001077091A3 Ns5b hcv polymerase inhibitors
03/21/2002WO2001072322A3 High dosage parenteral administration of lactoferrin
03/21/2002WO2001070694A8 Amorphous torasemide modification
03/21/2002WO2001068859A3 Il-17 receptor like molecules and uses thereof
03/21/2002WO2001068568A3 Il-8 receptor antagonists
03/21/2002WO2001068034A3 1, 2, 4-triazoloribonucleoside prodrugs and their administration to treat viral disease conditions
03/21/2002WO2001064715A3 Memno peptides, a process for their preparation and their use
03/21/2002WO2001064165A3 Il-8 receptor antagonists
03/21/2002WO2001062905A3 Integrin antagonists
03/21/2002WO2001060402A3 Proteosome influenza vaccine
03/21/2002WO2001055106A3 Novel melanocortin receptor agonists and antagonists
03/21/2002WO2001051638A3 Drug metabolizing enzymes
03/21/2002WO2001051510A3 G-csf conjugates
03/21/2002WO2001049775A3 Antisense antibacterial cell division composition and method
03/21/2002WO2001035943A3 Dextrose and insulin fluid formulation for intravenous infusion
03/21/2002WO2001030375A3 Use of gdnf for treating corneal defects
03/21/2002WO2000078772A3 Antibiotic agents
03/21/2002US20020035737 Cloning pigs using donor nuclei from differentiated cells
03/21/2002US20020035459 Pharmacokinetic-based drug design tool and method
03/21/2002US20020035258 Quinolone carboxylic acid derivatives
03/21/2002US20020035239 Active materials for grampositive bacteria, antibiotic resistance infections
03/21/2002US20020035161 O/W emulsions comprising micronized biologically active agents
03/21/2002US20020035147 Nervous system, psychological disorders
03/21/2002US20020035140 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
03/21/2002US20020035122 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives
03/21/2002US20020035102 Azetidine derivatives, their preparation and medicaments containing them
03/21/2002US20020035094 Substituted pyridine compounds and methods of use
03/21/2002US20020035088 Formulated at a certain pH in order to minimize or eliminate compatibility problems between tobramycin and xanthan gum; eye, nose, ear topical solutions
03/21/2002US20020035085 Administering a 2'-deoxy-beta-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof
03/21/2002US20020035081 Nucleic acid encoding a polypeptide of the virus' core protein having altered carboxyterminus, for reducing replication of a wild type hepadnavirus, by a dominant negative mechanism
03/21/2002US20020035073 For treatment of infections by Candida albicans
03/21/2002US20020035063 Derivatives of laspartomycin and preparation and use thereof
03/21/2002US20020035061 Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
03/21/2002US20020034779 Novel argS
03/21/2002US20020034734 Vaccine composition for preventing or treating hepatitis C
03/21/2002US20020034538 Liposomal benzoquinazolne thymidylate synthase inhibitor formulations
03/21/2002US20020034534 Receptor loading dosage form containing therapeutic agent and extended-release dosage form containing therapeutic agent administered concurrently
03/21/2002US20020034520 Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases
03/21/2002US20020034519 Modified bovine adenovirus having altered tropism
03/21/2002US20020034514 Administering microsphere of immunogens; enteric overcoatings
03/21/2002US20020034509 Methods and compositions for ameliorating the symptoms of sepsis
03/21/2002US20020034491 Administering cationic polymers
03/21/2002US20020034393 Vector
03/21/2002US20020033181 Treatment of hepatitis C using hyperthermia
03/21/2002DE10138935A1 Synthetische Verbindungen vom Nicht-Mucintyp oder ihre mit einem Träger konjugierten Verbindungen Synthetic compounds from non-mucin or its conjugated with a carrier compounds
03/21/2002DE10045047A1 Arzneimittel enthaltend aktiviertes Antithrombin III Medicines containing activated antithrombin III
03/21/2002DE10044648A1 Verfahren zur Vermehrung oder zur Entfernung von Cirocoviren aus biologischem Material Method of replication or removal of Cirocoviren from biological material
03/21/2002DE10044325A1 Neue MMP-2-Derivate als Inhibitoren des Integrins avbeta3 New MMP-2 derivatives as inhibitors of the integrin avbeta3
03/21/2002CA2422882A1 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
03/21/2002CA2422841A1 Methods for delaying recurrence of herpes virus symptoms
03/21/2002CA2422828A1 Novel tumor-associated marker
03/21/2002CA2422616A1 Gatifloxacin pentahydrate
03/21/2002CA2422603A1 Vectors for molecule delivery to cd11b expressing cells
03/21/2002CA2422597A1 T cell receptor transfer into a candidate effector cell or a precursor thereof
03/21/2002CA2422586A1 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
03/21/2002CA2422575A1 Composition comprising immunogenic microparticles
03/21/2002CA2422454A1 Compositions and methods for inducing specific cytolytic t cell responses
1 ... 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 ... 1798